The specialized pro-resolving lipid mediator Protectin D1 affects macrophages differentiation and activity in Adult-onset Still's disease and COVID-19, two hyperinflammatory diseases sharing similar transcriptomic profiles.
Adult-onset Still’s Disease
COVID-19
hyperinflammation
protectin D1
specialized pro-resolving mediators (SPMs)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
01
2023
accepted:
31
03
2023
medline:
10
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
COVID-19 and autoinflammatory diseases, such as Adult-onset Still's Disease (AOSD), are characterized by hyperinflammation, in which it is observed massive production and uncontrolled secretion of pro-inflammatory cytokines. The specialized pro-resolving lipid mediators (SPMs) family is one the most important processes counteracting hyperinflammation inducing tissue repair and homeostasis restoration. Among SPMs, Protectin D1 (PD1) is able to exert antiviral features, at least in animal models. The aim of this study was to compare the transcriptome of peripheral blood mononuclear cells (PBMCs) from patients with AOSD and COVID-19 and to evaluate the role of PD1 on those diseases, especially in modulating macrophages polarization. This study enrolled patients with AOSD, COVID-19, and healthy donors HDs, undergoing clinical assessment and blood sample collection. Next-generation deep sequencing was performed to identify differences in PBMCs transcripts profiles. Plasma levels of PD1 were assessed by commercial ELISA kits. Monocyte-derived macrophages were polarized into M1 and M2 phenotypes. We analyzed the effect of PD1 on macrophages differentiation. At 10 days, macrophages were analyzed for surface expression of subtypes markers by flow cytometry. Cytokines production was measured in supernatants by Bio-Plex Assays. In the transcriptomes from AOSD patients and COVID-19 patients, genes involved in inflammation, lipid catabolism, and monocytes activation were specifically dysregulated in AOSD and COVID-19 patients when compared to HDs. Patients affected by COVID-19, hospitalized in intensive care unit (ICU), showed higher levels of PD1 when compared to not-ICU hospitalized patients and HDs (ICU COVID-19 vs not-ICU COVID-19, p= 0.02; HDs vs ICU COVID-19, p= 0.0006). PD1 levels were increased in AOSD patients with SS ≥1 compared to patients with SS=0 (p=0.028) and HDs (p=0.048). PD1 is able to induce pro-resolutory programs in both AOSD and COVID-19 increasing M2 polarization and inducing their activity. In particular, PD1-treated M2 macrophages from AOSD and COVID-19 patients increased the production of IL-10 and enhanced homeostatic restoration through MIP-1β production.
Identifiants
pubmed: 37153620
doi: 10.3389/fimmu.2023.1148268
pmc: PMC10160453
doi:
Substances chimiques
Interleukin-10
130068-27-8
protectin D1
0
Chemokine CCL4
0
Cytokines
0
Docosahexaenoic Acids
25167-62-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1148268Informations de copyright
Copyright © 2023 Navarini, Vomero, Currado, Berardicurti, Biaggi, Marino, Bearzi, Corberi, Rigon, Arcarese, Leuti, Fava, Fogolari, Mattei, Ruscitti, Di Cola, Sambuco, Travaglino, Angeletti, Ursini, Mariani, Cipriani, Agrò, Iagnocco, Antonelli Incalzi, Maccarrone and Giacomelli.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Rev Immunol. 2016 Jan;16(1):51-67
pubmed: 26688348
Front Immunol. 2020 May 28;11:1130
pubmed: 32574264
Toxicol Appl Pharmacol. 2022 Aug 15;449:116089
pubmed: 35644268
Sci Rep. 2017 Dec;7(1):99
pubmed: 28273909
Eur J Med Res. 2023 Feb 25;28(1):100
pubmed: 36841793
Asia Pac Allergy. 2020 Apr 27;10(2):e21
pubmed: 32411586
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
BMC Med. 2016 Dec 1;14(1):194
pubmed: 27903264
Expert Rev Clin Immunol. 2017 Nov;13(11):1041-1047
pubmed: 28837367
Ann Rheum Dis. 2020 Sep;79(9):1152-1155
pubmed: 32719039
Allergy. 2021 Mar;76(3):626-628
pubmed: 32956495
Medicina (Kaunas). 2022 Jan 18;58(2):
pubmed: 35208467
PLoS One. 2020 Jul 9;15(7):e0235326
pubmed: 32645077
Ann Rheum Dis. 2020 Nov;79(11):1515-1516
pubmed: 32434816
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
Front Immunol. 2021 Feb 24;12:632238
pubmed: 33717168
Molecules. 2021 Nov 18;26(22):
pubmed: 34834062
Cureus. 2022 Nov 2;14(11):e31034
pubmed: 36475201
PLoS One. 2021 Aug 26;16(8):e0256226
pubmed: 34437568
Medicine (Baltimore). 1991 Mar;70(2):118-36
pubmed: 2005777
J Autoimmun. 2018 Sep;93:24-36
pubmed: 30077425
Nat Immunol. 2005 Dec;6(12):1191-7
pubmed: 16369558
J Rheumatol. 2018 Jun;45(6):864-872
pubmed: 29657144
J Clin Invest. 2020 May 1;130(5):2202-2205
pubmed: 32217834
Oncoimmunology. 2019 Nov 3;9(1):1683347
pubmed: 32002295
Cytokine. 2021 Oct;146:155640
pubmed: 34252872
J Immunol. 2005 Apr 1;174(7):4345-55
pubmed: 15778399
Adv Drug Deliv Rev. 2020;159:133-169
pubmed: 32628989
Front Immunol. 2022 Aug 26;13:953730
pubmed: 36090971
Cell. 2013 Mar 28;153(1):112-25
pubmed: 23477864
Semin Arthritis Rheum. 2021 Aug;51(4):858-874
pubmed: 34175791
J Biol Chem. 2015 Dec 25;290(52):30697-712
pubmed: 26546682
Rheumatology (Oxford). 2022 Dec 23;62(1):321-329
pubmed: 35438139
J Allergy Clin Immunol. 2018 Aug;142(2):691-695.e4
pubmed: 29698628
Front Immunol. 2021 Jul 21;12:720109
pubmed: 34367190
Ther Adv Musculoskelet Dis. 2021 Nov 24;13:1759720X211059598
pubmed: 34868356
Am J Clin Nutr. 2022 Sep 2;116(3):786-797
pubmed: 35849016
Semin Immunol. 2013 Dec 15;25(6):469-84
pubmed: 24275598
Autoimmun Rev. 2015 May;14(5):429-37
pubmed: 25599955
Science. 2020 Sep 4;369(6508):1210-1220
pubmed: 32788292
J Clin Invest. 2018 Aug 1;128(8):3568-3582
pubmed: 30010619
Sci Rep. 2018 Sep 3;8(1):13129
pubmed: 30177769
Front Pharmacol. 2020 Nov 19;11:569849
pubmed: 33424586
Clin Rheumatol. 2019 Nov;38(11):3205-3210
pubmed: 31236746
Immunopharmacol Immunotoxicol. 2021 Aug;43(4):395-409
pubmed: 34057871
Haematologica. 2020 Aug;105(8):2056-2070
pubmed: 31780628